![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1260099
¼¼°èÀÇ IOL ½ÃÀå(2023³â) : 2022-2028³â ºÐ¼®2023 IOL Market Report: Global Analysis for 2022 to 2028 |
¼¼°èÀÇ IOL ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ¼¼°èÀÇ ¹é³»Àå ÀÌȯÀ²°ú ¹é³»Àå ¼ö¼ú °³¿ä, ÇâÈÄ 5³â°£ ¹é³»Àå ¼ö¼ú °Ç¼ö ¿¹Ãø, ºÎ¹®º° ±¹°¡¡¤Áö¿ªº° ¸ÅÃâ ¿¹Ãø, ±â¼ú °³¹ß µ¿Çâ µîÀ» Á¦°øÇÕ´Ï´Ù.
The "2023 IOL Market Report" examines the first-ever projected global decline in PC-IOL procedures and penetration in 2023-led by significantly reduced reimbursement in Japan and South Korea-and outlines the numerous countervailing positive and negative factors that will shape the IOL market over the next five years. One of these factors is refractive lens exchange, which has growing importance in driving premium IOL penetration.
The report also thoroughly examines the RxSight post-op adjustable IOL, which has become the fastest growing IOL in the world (though from a small base) with sales only in the United States.
In addition, the report adds new analysis into factors shaping growing adoption of immediate sequential bilateral cataract surgery (ISBCS) and same-day/next day cataract surgery.
The "2023 IOL Market Report" provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 11 categories of IOLs: commodity monofocal, enhanced monofocal/intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, postoperatively adjustable, and phakic IOLs. Additionally, 34 companies are profiled, with discussion of their products, strategic market position, background, and outlook.
The "2023 IOL Market Report" offers a comprehensive look at the global IOL market, with eight regional/economic breakouts. The following information is included in this report:
Bill Freeman has more than 35 years of experience developing, manufacturing, and marketing cataract surgery products. He has held key executive positions at four firms that produce ophthalmic surgical devices.
Bill's career in ophthalmology began in the 1970s. As president of Cavitron Surgical Systems, he worked with Dr. Charles Kelman in developing and marketing the world's first phacoemulsifier system. While highly controversial in the 1970s, phacoemulsification gradually became the preferred cataract removal technique in the early 1980s. For many years, Cavitron led the cataract instrumentation market.
CooperVision purchased Cavitron in the early 1980s, and Bill joined the company as president of the surgical division. CooperVision expanded its product line to include a wide variety of cataract surgical products-IOLs, viscoelastic solutions, disposable devices, lasers, and custom packs-and became the market leader in many product categories.